Pfizer Corex Ban

Drug maker Pfizer is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio.

The Delhi High Court on Thursday reserved its verdict in over 450 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well-known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

Government on Monday sought vacation of Delhi High Court's interim order staying the ban on some fixed dose combinations (FDC) medicines, saying it would be "against public interest and patient safety" and alleging that the drug firms' sole objective was to make profits.

Pharma majors Abbott Healthcare and Macleods Pharmaceuticals on Tuesday got interim relief from the Delhi High Court which stayed till March 21 Government's decision banning sale of certain combination medicines of the two companies.

Pfizer shares were headed for their second successive fall on Tuesday following following a ban on its Corex cough syrup. Pfizer shares sank 9 per cent yesterday.

Delhi High Court granted U.S. drugmaker Pfizer an interim injunction on a ban on its popular cough syrup Corex, days after the government ordered it to be prohibited citing a potential risk to humans.

The Delhi High Court has said that for now, a government ban on popular cough syrup Corex, made by US pharma Pfizer, will not hold. The court will next hear the case on Monday.

The High Court will hear the case in a week. The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend prohibiting the sale and manufacture of 344 combination drugs blacklisted by a panel of experts.

The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans.

Health Ministry has banned about 344 fixed dose combination drugs, including cough syrups compositions, saying they involve "risk" to humans and safer alternatives were available.

US pharmaceutical giant Pfizer Inc's India unit said on Monday it had stopped selling its popular Corex cough syrup, after regulators banned it saying it was likely to pose a risk to humans.

Shares in the Indian units of US-based drugmakers Pfizer and Abbott Laboratories fell as much as 5 per cent on Monday after authorities imposed a ban on their codeine-based cough syrups, saying they posed a health risk.

US pharmaceutical giant Pfizer Inc's India unit said on Monday it had stopped selling its popular Corex cough syrup, after regulators banned it saying it was likely to pose a risk to humans.

Drug maker Pfizer is planning to extend its Corex brand to a series of new products to treat respiratory ailments as part of a revamp of its product portfolio.

The Delhi High Court on Thursday reserved its verdict in over 450 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well-known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

Government on Monday sought vacation of Delhi High Court's interim order staying the ban on some fixed dose combinations (FDC) medicines, saying it would be "against public interest and patient safety" and alleging that the drug firms' sole objective was to make profits.

Pharma majors Abbott Healthcare and Macleods Pharmaceuticals on Tuesday got interim relief from the Delhi High Court which stayed till March 21 Government's decision banning sale of certain combination medicines of the two companies.

Pfizer shares were headed for their second successive fall on Tuesday following following a ban on its Corex cough syrup. Pfizer shares sank 9 per cent yesterday.

Delhi High Court granted U.S. drugmaker Pfizer an interim injunction on a ban on its popular cough syrup Corex, days after the government ordered it to be prohibited citing a potential risk to humans.

The Delhi High Court has said that for now, a government ban on popular cough syrup Corex, made by US pharma Pfizer, will not hold. The court will next hear the case on Monday.

The High Court will hear the case in a week. The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend prohibiting the sale and manufacture of 344 combination drugs blacklisted by a panel of experts.

The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans.

Health Ministry has banned about 344 fixed dose combination drugs, including cough syrups compositions, saying they involve "risk" to humans and safer alternatives were available.

US pharmaceutical giant Pfizer Inc's India unit said on Monday it had stopped selling its popular Corex cough syrup, after regulators banned it saying it was likely to pose a risk to humans.

Shares in the Indian units of US-based drugmakers Pfizer and Abbott Laboratories fell as much as 5 per cent on Monday after authorities imposed a ban on their codeine-based cough syrups, saying they posed a health risk.

US pharmaceutical giant Pfizer Inc's India unit said on Monday it had stopped selling its popular Corex cough syrup, after regulators banned it saying it was likely to pose a risk to humans.